Zobrazeno 1 - 10
of 194
pro vyhledávání: '"her2-negative breast cancer"'
Publikováno v:
Cancer Management and Research, Vol Volume 16, Pp 691-701 (2024)
Lianru Zhang,1,2,* Jie Xiao,1,2,* Yishan Li,1,2,* Baorui Liu,1,2 Li Xie1,2 1The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, People’s Republic of China;
Externí odkaz:
https://doaj.org/article/371d7cbae2394cc78d1f6c65e3a366f4
Autor:
Antonella Ferro, Michela Campora, Alessia Caldara, Delia De Lisi, Martina Lorenzi, Sara Monteverdi, Raluca Mihai, Alessandra Bisio, Mariachiara Dipasquale, Orazio Caffo, Yari Ciribilli
Publikováno v:
Journal of Clinical Medicine, Vol 13, Iss 12, p 3611 (2024)
Estrogen receptor (ER)-positive breast cancer (BC) is the most common BC subtype. Endocrine therapy (ET) targeting ER signaling still remains the mainstay treatment option for hormone receptor (HR)-positive BC either in the early or in advanced setti
Externí odkaz:
https://doaj.org/article/1696586c97d142aca8f2bdc3d7bb02bd
Autor:
Sofia Schaeffer, Christian Lutz, Michael Dobbie, Luigi M. Terracciano, Matthias Matter, Jürg Vosbeck, Markus H. Heim, Christine Bernsmeier
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundIdiosyncratic drug-induced liver injury (DILI) is a rare, unpredictable hepatic adverse event and the most common cause of acute liver failure in Europe and the US. Ribociclib is a potent Cyclin-dependent kinase 4 and 6 (CDK4/6)-inhibitor a
Externí odkaz:
https://doaj.org/article/89aa1a97aca843faafac9d5b4d159c2c
Publikováno v:
Cancers, Vol 16, Iss 10, p 1801 (2024)
Breast cancer is the most common cancer type in women. The vast majority of breast cancer patients have hormone receptor-positive (HR+) tumors. In advanced HR+ breast cancer, the combination of endocrine therapy with cyclin-dependent kinase 4/6 (CDK4
Externí odkaz:
https://doaj.org/article/1710fc3ff1d54b4e94fb5c5ab4793ad8
Autor:
Board Editorial
Publikováno v:
Современная онкология, Vol 24, Iss 1, Pp 24-29 (2022)
The Satellite Symposium of Novartis Pharma was held on January 28th,2022, within the framework of the RUSSCO Big Conference "Breast Cancer". It was dedicated to the diagnostics and treatment of patients with hormone receptor-positive HER2-negative ad
Externí odkaz:
https://doaj.org/article/bff9eb124e93484182cd3e91851d4504
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundIn vivo and in vitro experiments have demonstrated that diagnostic ultrasound combined with microbubbles (USMB) can enhance tumor chemotherapy, but few clinical studies have explored the effect of USMB in human HER2-negative breast cancer.
Externí odkaz:
https://doaj.org/article/e58ee07673474009ad1d38b44b230883
Publikováno v:
Cancer Medicine, Vol 10, Iss 13, Pp 4658-4674 (2021)
Abstract Aims Prognosis of patients for human epidermal growth factor receptor 2 (HER2)‐negative breast cancer post neoadjuvant chemotherapy is not well understood. The aim of this study was to develop a novel pharmacophore‐based signature to bet
Externí odkaz:
https://doaj.org/article/894293fc990c481aaae324baa300746b
Autor:
Wei Wu, Jiewen Chen, Heran Deng, Liang Jin, Zhanghai He, Nanyan Rao, Yan Nie, Yandan Yao, Yaping Yang, Fengxi Su, Jieqiong Liu
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background Here we evaluated the feasibility, efficacy, tolerability, and treatment-mediated immune modulation of neoadjuvant everolimus plus letrozole versus chemotherapy in treating postmenopausal patients with ER-positive, HER2-negative b
Externí odkaz:
https://doaj.org/article/6177ffceb2014b5b9cae1e9c928e4cd6
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-10 (2021)
Abstract Background There is currently no clinical trial data regarding the efficacy of everolimus exemestane (EE) following prior treatment with CDK4/6 inhibitors (CDK4/6i). This study assesses the use and efficacy of everolimus exemestane in patien
Externí odkaz:
https://doaj.org/article/149b6b346a3a4fc299d9d8918e091ff3
Publikováno v:
Journal of Clinical Medicine, Vol 12, Iss 4, p 1588 (2023)
The optimal treatment regimen for breast cancer patients with gBRCA mutations remains controversial given the availability of numerous options, such as platinum-based agents, polymerase inhibitors (PARPis), and other agents. We included phase II or I
Externí odkaz:
https://doaj.org/article/712c29581e494ad998042e80554d5636